Potential therapeutic roles for antibody mixtures

Expert Opinion on Biological Therapy

Volumn 13, Issue 10, 2013, Pages 1347-1352

  Raju, T Shantha ^a   Strohl, William R ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Antibody; Antibody mixtures; Bispecific; Chimeric; Combination drugs; DVD Ig; FAb; Fc; Human; Humanized; Intravenous immunoglobulins; Multispecific antibodies

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; BISPECIFIC ANTIBODY; BRENTUXIMAB VEDOTIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ETANERCEPT; FUTUXIMAB; GOLIMUMAB; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; PERTUZUMAB; RANIBIZUMAB; RECOMBINANT ANTIBODY; RITUXIMAB; ROZROLIMUPAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SYM 006; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB; XOMA 3 AB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ENGINEERING; ANTIGEN BINDING; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; BIOTECHNOLOGY; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MARKETING; DRUG MIXTURE; DRUG RECEPTOR BINDING; DRUG TARGETING; HODGKIN DISEASE; HUMAN; IMMUNOTHERAPY; MONOTHERAPY; NONHUMAN; POLYPHARMACY; PROTEIN GLYCOSYLATION; RETINA MACULA DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN G; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES;

EID: 84884272080     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.822065     Document Type: Review

References (20)

1. Strohl WR, Strohl LM. Therapeutic antibody engineering: Current and future advances driving the strongest growth area in the pharma industry. Woodhead Publishing Series in Biomedicine No. 11 Woodhead Publishing; Cambridge: 2012
2. Reichert JM. Marketed therapeutic antibodies compendium. MAbs 2012;4:413-15
3. Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008;20:471-8
4. Govindan SV, Goldenberg DM. Designing immunoconjugates for cancer therapy. Expert Opin Biol Ther 2012;12:873-90
5. Weidle UH, Schneider B, Georges G, Brinkmann U. Genetically engineered fusion proteins for treatment of cancer. Cancer Genomics Proteomics 2012;9:357-72
6. Raju TS, Briggs JB, Chamow SM, et al. Glycoengineering of therapeutic glycoproteins: In vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues. Biochemistry 2001;40:8868-76
7. Spadaro A, Lubrano E, Ferrara N, Scarpa R. EtanercePTin psoriatic arthritis. J Rheumatol Suppl2012;89:74-6
8. Dimitrov DS. Therapeutic proteins. Methods Mol Biol 2012;899:1-26
9. Labrijn AF, Meesters JI, de Goeij BE, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci USA 2013;110:5145-50
10. Jakob CG, Edalji R, Judge RA, et al. Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig;) molecule. MAbs 2013;5:358-63
11. Günther G, Dreger B. Post-marketing observational study on 5% intravenous immunoglobulin therapy (Alphaglobin;/ Flebogamma;) in secondary immunodeficiency with recurrent serious bacterial infections. Microbiol Immunol. 2013;doi:10.1111/1348-0421.12060
12. Anthony RM, Ravetch JV. A novel role for the IgG Fc glycan: The anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol 2010;30(Suppl1):S9-14
13. Polat ZA, Walochnik J, Obwaller A, et al. Miltefosine and polyhexamethylene biguanide: A new drug combination for the treatment of Acanthamoeba keratitis. Clin Experiment Ophthalmol 2013; doi:10.1111/ceo.12120
14. Olender S, Wilkin TJ, Taylor BS, Hammer SM. Advances in antiretroviral therapy. Top Antivir Med 2012;20:61-86
15. Meng Q, Garcia-Rodriguez C, Manzanarez G, et al. Engineered domain-based assays to identify individual antibodies in oligoclonal combinations targeting the same protein. Anal Biochem 2012;430:141-50
16. Haurum JS. Recombinant polyclonal antibodies: The next generation of antibody therapeutics̈Drug Discov Today 2006;11:655-60
17. Skartved NJ, Jacobsen HJ, Pedersen MW, et al. Preclinical pharmacokinetics and safety of Sym004: A synergistic antibody mixture directed against epidermal growth factor receptor. Clin Cancer Res 2011;17:5962-72
18. Byrd JC, Kipps TJ, Flinn IW, et al. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010;115(3):489-95
19. Raut AS, Prabhu RH, Patravale VB. Psoriasis clinical implications and treatment: A review. Crit Rev Ther Drug Carrier Syst 2013;30:183-216
20. Koefoed K, Steinaa L, Søderberg JN, et al. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. MAbs 2011;3:584-95